Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant With Colic Not Responding to Conventional Treatment (nocry-a)

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Menarini Group
ClinicalTrials.gov Identifier:
NCT01309009
First received: March 2, 2011
Last updated: November 5, 2012
Last verified: November 2012

March 2, 2011
November 5, 2012
February 2011
November 2012   (final data collection date for primary outcome measure)
Absolute change of the mean daily crying and fussing time for three consecutive days while on treatment versus baseline. [ Time Frame: one week ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01309009 on ClinicalTrials.gov Archive Site
  • Percentage of 'responder' babies at the end of treatment period. [ Time Frame: one week ] [ Designated as safety issue: No ]
  • Absolute change in the overall parental judgment after the first dose of treatment, at the end of treatment, and after treatment discontinuation versus baseline. [ Time Frame: ten days ] [ Designated as safety issue: No ]
  • Safety and tolerability will be assessed in terms of frequency and severity of AEs as well as frequency of clinically significant changes in physical examination and lab test. [ Time Frame: up to four weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant With Colic Not Responding to Conventional Treatment
Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Efficacy and Safety of Oral Administration of Nepadutant in Infant Colic Babies Not Responder to Conventional Treatments

This phase IIa study is designed as a multi-centre, single country, randomised, double-blind, placebo controlled study in three parallel groups, with the aim to evaluate the efficacy and safety of Nepadutant given at two oral doses once daily for seven days in comparison to placebo in the treatment of infantile colic.

Infant colic is a functional gastrointestinal disorders which affects up to the 30% of the infant population; it is primarily characterised by excessive inconsolable crying starting without any apparent cause and lasting for several hours per day.

Current non pharmacological interventions (e.g. message, restriction in maternal diet in breast-feeding infants) and pharmacological treatments (simethicone, antimuscarinic drugs) are largely unsatisfactory.

In animal models, Nepadutant reverse the exaggerated intestinal motility and sensitivity, induced by different stimuli, without producing inhibitory effects on these functions at baseline, suggesting that Nepadutant could have a therapeutic effect with no interference on physiological gastrointestinal transit.

This phase IIa study is designed to evaluate the efficacy of Nepadutant paediatric oral solution given once daily at two doses in comparison to placebo.

The experimental clinical phase encompasses the following periods:

  • Screening period (no study medication) to be done 7 to 4 days prior to randomisation
  • Treatment period, lasting seven days with once daily administration
  • Post treatment period, lasting seven days A safety follow-up visit will be performed approximately 1 month after the first administered dose.
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Infantile Colic
  • Drug: Nepadutant oral solution
    Oral administration once daily for 7 days
  • Drug: Placebo matching Nepadutant oral solution
    Oral administration once daily for 7 days
  • Experimental: Nepadutant High Dose
    Intervention: Drug: Nepadutant oral solution
  • Experimental: Nepadutant Low Dose
    Intervention: Drug: Nepadutant oral solution
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo matching Nepadutant oral solution
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
January 2013
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy infants with diagnosis of infant colic according to the following modified Wessel criterion "paroxysm of irritability, fussing or crying that start and stop without obvious cause for >3h/day, >3 days/week for one week"
  • Age ≥ 6 weeks and < 4 months
  • No adequate response to conventional pharmacological or non-pharmacological treatment alternatives for infant colic
  • Infants exclusively breast-fed.
  • Normal growth
  • Willingness to refrain from use of antimuscarinic drugs, simethicone, dimethicone or antiacids during the study period

Exclusion Criteria:

  • Clinical evidence of allergies or other diseases which may cause crying and/or fussiness or may interfere with absorption or clearance of the drug.
  • Suspect of gastroesophageal reflux disease (GERD)
  • Formula fed or mixed fed infants.
Both
6 Weeks to 4 Months
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01309009
NIC-05 (NOCRY-a)
No
Menarini Group
Menarini Group
Not Provided
Study Chair: Paolo Lionetti, MD Servizio di Gastroenterologia dell'Azienda Ospdedaliero - Universitaria Anna Meyer di Firenze
Menarini Group
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP